

13th February, 2018

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata – 700 001

To,
Dy. General Manager,
Corporate Relationship Department,
ESE Limited,
P. J. Tower,
Mumbai – 400 001

Sub: - Submission of Unaudited Financial Result for the 3rd Quarter ended 31st December, 2017 pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements), Regulations 2015

Dear Sir,

Pursuant to Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the meeting of the Board of Directors of the Company held at its Registered Office of the Company on Tuesday, 13th February, 2018 (which commenced at 11.00 A.M. and concluded at 12.55 P.M.) wherein they have approved the following :-


1. Unaudited Financial Results for the 3rd quarter ended 31st December, 2017 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. Limited Review Report by the Statutory Auditors on Unaudited Financial Result for the 3rd Quarter ended 31st December, 2017.

The above information is available on Company's website www.adinathbio.com and on the Stock Exchange website: www.bseindia.com and www.cse-india.com.

We request you to take on record and acknowledge the same.

Thanking you,

For Adinath Bio-Labs Limited


(Kishan Singh)
Whole Time Director
DIN: 07526266



Encl. As Above

Adinath Bio-Labs Limited
 CIN: L24230WB1982PLC034492

Statement of Standalone Unaudited Financial Results for the quarter and nine months ended 31st December, 2017

PART I		Amount (In Rs.)				
Sl. No.	Particulars	Unaudited				
		Quarter Ended			Nine Months Ended	
		31-12-2017	30-09-2017	31-12-2016	31-12-2017	31-12-2016
1	Income from operations					
	(a) Net Sales / income from operations	-	-	11,44,228	11,22,670	46,14,786
	(b) Other Income	1,60,000	1,20,000	-	2,80,000	-
	Total income from operations (net)	1,60,000	1,20,000	11,44,228	14,02,670	46,14,786
2	Expenses					
	(a) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	(b) Employee benefits expense	1,60,431	1,90,050	3,86,748	7,03,835	15,74,895
	(c) Finance Cost	-	-	-	-	-
	(d) Depreciation and amortisation expense	2,15,093	2,14,017	2,86,195	6,41,125	8,58,585
	(e) Other expenses	347,76,326	3,88,455	4,17,354	356,94,179	19,08,814
	Total expenses	351,51,850	7,92,522	10,90,297	370,39,139	43,42,294
3	Profit / (Loss) from operations before Exceptional & Extraordinary Items (1-2)	(349,91,850)	(6,72,522)	53,931	(356,36,469)	2,72,492
4	Exceptional & Extraordinary Items	-	-	-	-	-
5	Profit / (Loss) before Tax (3 ± 4)	(349,91,850)	(6,72,522)	53,931	(356,36,469)	2,72,492
6	Tax expense					
	Current Tax	-	-	-	-	-
	Deferred Tax	-	-	-	-	-
	Earlier Years	-	-	-	-	-
	Total Tax Expenses	-	-	-	-	-
7	Net Profit/(Loss) after tax(5 ± 6)	(349,91,850)	(6,72,522)	53,931	(356,36,469)	2,72,492
8	Other Comprehensive Income / (Loss)	-	-	-	-	-
9	Total Comprehensive Income / (Loss) (7 ± 8)	(349,91,850)	(6,72,522)	53,931	(356,36,469)	2,72,492
10	Paid-up equity share capital	2207,42,560	2207,42,560	2207,42,560	2207,42,560	2207,42,560
	(Face Value of the Share shall be indicated)(₹)	1	1	1	1	1
11	Earnings Per Share (not annualised):					
	Basic & Diluted	(0.16)	(0.00)	0.00	(0.16)	0.00



Notes:

- 1 The above Unaudited Financial Results have been reviewed by the Audit Committee at their meeting held on 12th February, 2018 and adopted by the Board of Directors at their meeting held on 13th February, 2018.
- 2 The results are based on the financial statements prepared by the Company's Management in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder. Beginning with 01st April, 2017, the Company has for the first time adopted Ind AS with the transition date of 01st April, 2016. The financial results are made available on the company's website www.adinathbio.com. Financial Results of all the periods presented have been prepared in accordance with the recognition and the measurement principles of IND AS - 34 (Interim Financial Reporting).
- 3 The Company is engaged in the Business of Trading in Commodities and its allied products and therefore has only one reportable segment as envisaged by Ind AS 108 'Operating Segment'.
- 4 The Statutory Auditors of the Company have conducted a limited review of the above unaudited standalone financial results of the Company for the quarter and nine months ended December 31, 2017 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The figures for the corresponding quarter and nine months ended 31st December 2016, including the reconciliation of profit under Ind-AS of the corresponding quarter/period with the profit reported under previous GAAP (as stated above), have not been subjected to limited review. The management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.

- 5 Provisions for taxations will be made at the end of the year.
- 6 An amount of Rs.345.00 lakhs have been provided and charged to profit and loss account on account of fair valuation of financial instruments for the quarter ended 31st December, 2017.
- 7 The statement does not contain Ind AS compliant results for the previous year ended March 31, 2017 as the same is not mandatory as per SEBI circular CIR/CFD/FAC/62/2016 dated 05th July, 2016.
- 8 Reconciliation of Profit, as previously reported under IGAAP to Ind-AS for the quarter and nine months ended on 31st December 2016 is given below:

Particulars	Corresponding 3 months ended in the previous year ended December 31, 2016	Corresponding nine months ended on December 31, 2016
Net Profit/ (Loss) for the quarter under previous Indian GAAP	53,931	2,72,492
Add/ (Less): Adjustments with respect to Ind AS compliance	-	-
Net Profit/ (Loss) for the quarter under IND AS	53,931	2,72,492


The reconciliation statement has been provided in accordance with circular CIR/CFD/FAC/62/2016 issued by SEBI dated July 05, 2016 on account of implementation of Ind-AS by listed companies.

- 9 Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period's classification / disclosure.

Date: 13th February, 2018
Place: Kolkata



By order of the Board
For Adinath Bio-Labs Limited


Kishan Singh
Whole-Time Director
DIN No.: 07526266

Limited Review Report on quarterly Unaudited Financial Results of Adinath Bio-Labs Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors of
Adinath Bio-Labs Limited

We have reviewed the accompanying Statement of Unaudited Financial Results ('the Statement') of Adinath Bio-Labs Limited ("the Company") for the quarter and nine months ended 31 December, 2017 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 13 February, 2018. Our responsibility is to issue a Report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' ("the Standard"), issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with applicable Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Mohindra Arora & Co.
Chartered Accountants
Firm registration No: 006551M



Ashok Katial
Partner

Membership No: 09096

Place : Mumbai
Date : February 13, 2018